Karus is focused on the design and development of two innovative classes of small molecule cancer therapies. These are potent, selective, orally-active inhibitors of the PI3K-p110β/δ and HDAC6 enzymes, with a primary focus on the treatment of a diverse range of solid and hematological cancers.

Our highly experienced management team has a track record of scientific excellence in small molecule drug discovery and development. This has produced therapeutic programs with the potential to be either first- or best-in-class agents for the treatment of cancer. These innovative programs are underpinned by a broad intellectual property portfolio.

We operate an outsourced business model: retaining drug design, experimental chemistry and in vitro biology research in-house, whilst outsourcing a significant proportion of our R&D activities to a network of internationally-recognised CROs. This approach has allowed us to remain capital-efficient and flexible whilst advancing multiple R&D programs through key value inflection points.

Our Company has a history of strong financial management and is backed by some of the biotech industry’s most experienced investors. By focusing our financial resources on creating value in our therapeutic programs, we have established a strong track-record of delivering key R&D goals on time and to budget.

Karus is supported by a syndicate of top-tier investors from the US and Europe: